Alzheimer's Disease Pipeline Market Diagnostic Tests and Company Profiles Report

PUNE, India, August 16, 2018 /PRNewswire/ --

Alzheimer's Disease Pipeline Review, H2 2018 report added in ReportsnReports. The Pharmaceutical and Healthcare latest pipeline guide provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Browse 85 List of Data Tables and Figures spread through 1333 Pages and In-depth TOC on Alzheimer's Disease Pipeline Market Review, H2 2018 Report at https://www.reportsnreports.com/reports/1601299-alzheimers-disease-pip ...

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 25, 56, 53, 3, 276, 102 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 41 molecules, respectively.

Alzheimer Diagnostic Tests Companies and Product Overview: AC Immune SA, Acobiom, Acumen Pharmaceuticals Inc, Adlyfe Inc, Admit Therapeutics SL, ADx NeuroSciences NV, Aelan Cell Technologies, Albert Ludwigs University of Freiburg, Alere Inc, Alzhyme Pty Ltd and more profiles is in report.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.